Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
Komal Jhaveri, MD, FACP
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
Virginia Kaklamani, MD, DSc
Oral SERDs and PROTACs in ER+/HER2− mBC: Testing Smarter, Treating Better
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
Unmet Needs in Endocrine Therapy: Rethinking the HR+/HER2- mBC Treatment Roadmap
Routes Reconsidered: A Case-Based Debate in SERD Selection
Giuseppe Curigliano, MD, PhD
Doublet or Triplet? A Case-Based Debate in First-Line Choices for HR+/HER2- mBC
Spotlight on Europe: Adapting the Evidence
Safety of CDK4/6 Inhibitors: Anticipation, Prevention, and Management of Adverse Events
The Future of Oral SERDs: Combination Strategies
Beyond Fulvestrant: Oral SERDs Redefining ER Targeting
Spotlight on Asia-Pacific: Practice Beyond Borders
Hiraji Iwata, MD, PhD
Spotlight on Latin America: Closing the Gap
Cynthia Villarreal-Garza, MD, DSc
Breaking Down the Benchmarks: Pivotal Data on First-Line CDK4/6 Inhibitors
From Data to Debate: Global Perspectives on HR+/HER2- mBC Care
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.